Entecavir-13C2,15N

• UNSPSC Description:

  Entecavir-13C2,15N (BMS200475-13C2,15N; SQ34676-13C2,15N) is a 13C- and 15N-labeled Entecavir (HY-13623). Entecavir (SQ 34676; BMS 200475) is a potent and selective inhibitor of HBV, with an EC50 of 3.75 nM in HepG2 cell.

• Target Antigen:

  HBV; Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Anti-infection;Others

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/entecavir-13c2-15n.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O[C@H]([C@H]1CO)C[C@H](N2[13C]3=C([13C](NC(N)=N3)=O)[15N]=C2)C1=C

• Molecular Weight:

  280.26

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246.|[2]Innaimo SF, et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997 Jul;41(7):1444-9.|[3]Rivkin A, et al. A review of entecavir in the treatment of chronic hepatitis B infection. Curr Med Res Opin. 2005 Nov;21(11):1845-57.|[4]Genovesi EV, et al. Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother. 1998 Dec;42(12):3209-18.

• Shipping Conditions:

  Room temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen)

• Clinical Information:

  No Development Reported